Artificial intelligence is rapidly transforming drug development, manufacturing, and quality systems—but regulatory expectations are evolving just as quickly.
In 2026, the U.S. Food and Drug Administration is placing increased emphasis on how AI-enabled systems are validated, controlled, and maintained within regulated environments. As organizations adopt AI across clinical, operational, and quality functions, regulators are focusing on ensuring these technologies meet the same standards of reliability, traceability, and compliance as traditional systems.
AI is no longer viewed as experimental. It is now subject to inspection.
Why AI Validation Is Becoming a Regulatory Priority
AI systems are being used to support critical decisions, including patient selection in clinical trials, predictive maintenance in manufacturing, and deviation trending in quality systems.
Because these systems can directly impact product quality and patient safety, regulators expect organizations to demonstrate that AI outputs are accurate, consistent, and scientifically justified.
Unlike traditional software, AI models may evolve over time as new data is introduced. This creates challenges in maintaining a validated state—a foundational requirement in regulated industries.
The FDA is increasingly evaluating whether organizations have appropriate controls in place to manage this complexity.
What FDA Inspectors Are Looking For
During inspections, regulators are focusing on how AI systems are governed throughout their lifecycle—not just how they are initially implemented.
Key areas of focus include:
- Model validation and performance verification, ensuring outputs are reliable and reproducible
- Data integrity and training data controls, including data sources, quality, and bias mitigation
- Change management for evolving models, particularly for systems that continuously learn
- Documentation and traceability, demonstrating how decisions are made and supported
- User oversight and human review, ensuring AI outputs are appropriately evaluated before action
These expectations reflect a broader shift toward accountability in AI-driven decision-making.
Challenges in Maintaining a Validated State
One of the most significant challenges organizations face is maintaining validation as AI systems evolve.
Traditional validation approaches assume systems remain static. AI models, however, may update based on new inputs, requiring ongoing monitoring and periodic revalidation.
Without structured controls, this can lead to gaps in compliance, including undocumented changes, inconsistent performance, or lack of traceability.
Organizations must rethink validation as a continuous process rather than a one-time activity.
Integrating AI Into Quality and Compliance Frameworks
To meet regulatory expectations, AI systems must be fully integrated into existing quality management systems.
This includes aligning AI governance with:
- Computer system validation (CSV) or computer software assurance (CSA) frameworks
- Data integrity policies and procedures
- Risk management processes
- Deviation and CAPA systems
- Internal audit and monitoring programs
By embedding AI into established compliance structures, organizations can better manage risk and demonstrate control during inspections.
The Shift Toward Continuous Monitoring
AI adoption is driving a broader shift from static validation to continuous monitoring.
Organizations are expected to track model performance over time, identify drift or anomalies, and implement corrective actions when needed.
This requires not only technical capabilities, but also strong cross-functional collaboration between quality, regulatory, IT, and data science teams.
Continuous monitoring ensures that AI systems remain reliable, compliant, and aligned with intended use.
How EMMA International Supports AI Validation and Compliance
At EMMA International, we support organizations in implementing and governing AI-enabled systems within regulated environments.
Our teams help design validation strategies, establish data integrity controls, develop governance frameworks, and align AI systems with regulatory expectations.
As AI becomes more embedded in life sciences, organizations that prioritize structured validation and compliance will be best positioned to scale innovation while maintaining regulatory confidence.
References
U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Drug Development.
U.S. Food and Drug Administration. Computer Software Assurance for Production and Quality System Software.
International Society for Pharmaceutical Engineering (ISPE). GAMP 5 Guidance.
